RxDoctor Payments Data

Thomas Samaras, MD

Family Medicine · Virginia Beach, VANPI 1821007550

Payments from drug & device makers

$14,324in general payments, 2019–2025

Across 439 payments — averaging $32.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • Novo Nordisk$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Boehringer Ingelheim$742
  • plus $6K from 36 others

What the payments were for

  • Food & beverage$14,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,324 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$206,299
Medicare patients
501
Services billed
2,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide34$74,797
TrulicityDulaglutide46$67,526
FarxigaDapagliflozin Propanediol64$55,396
JardianceEmpagliflozin43$55,283
EliquisApixaban38$32,994
VascepaIcosapent Ethyl44$32,548
OzempicSemaglutide34$32,282
JanuviaSitagliptin Phosphate25$23,983
Repatha SureclickEvolocumab16$19,303
XareltoRivaroxaban22$17,228
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$15,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,974
Icosapent Ethyl20$10,165
NexletolBempedoic Acid11$8,942
Ezetimibe204$6,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,575$107,07968 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,457$74,84696 claims
Lilly USA, LLCTrulicity$721$67,52646 claims
Boehringer IngelheimJardiance$742$55,28343 claims
PfizerEliquis$657$32,99438 claims
MerckJanuvia$273$23,98325 claims
Johnson & JohnsonXarelto$1,048$17,22822 claims
GSKTrelegy Ellipta$412$14,97420 claims
Esperion Therapeutics, Inc.Nexletol$185$8,94211 claims
AbbVieSynthroid$1,090$2,76440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →